---
title: "InnoCore Appoints Hans de Backer as New CEO to Accelerate Global Expansion in Long Acting Injectable Drug Development"
id: "1787"
type: "post"
slug: "innocore-appoints-hans-de-backer-as-new-ceo-to-accelerate-global-expansion-in-long-acting-injectable-drug-development"
published_at: "2026-02-02T10:02:50+00:00"
modified_at: "2026-04-21T14:05:27+00:00"
url: "https://innocorepharma.com/news-events/innocore-appoints-hans-de-backer-as-new-ceo-to-accelerate-global-expansion-in-long-acting-injectable-drug-development/"
markdown_url: "https://innocorepharma.com/news-events/innocore-appoints-hans-de-backer-as-new-ceo-to-accelerate-global-expansion-in-long-acting-injectable-drug-development.md"
taxonomy_category:
  - "Latest News"
  - "Life at Innocore"
---

Groningen, The Netherlands — 02 February 2026

# InnoCore Appoints Hans de Backer as New CEO to Accelerate Global Expansion in Long Acting Injectable Drug Development

# InnoCore Appoints New CEO

Groningen, the Netherlands — 02 February 2026

InnoCore Pharmaceuticals announced the appointment of Hans de Backer as its new Chief Executive Officer today. Hans joins the company with a proven track record as a strategy‑driven business leader, recognized for delivering sustainable growth, shepherding complex organizations, and building energized, high‑performance teams.

Hans previously held senior leadership roles at Aspen Pharmacare and Biosynth, where he successfully scaled life‑sciences and manufacturing businesses across multiple international markets. His experience spans commercial leadership, operational excellence, strategic partnerships, and business transformation.

Hans’s appointment as CEO of InnoCore reflects and reinforces the company’s ambition to become the go‑to partner for long-acting injectables (LAI) development for biologics and peptides. With the rapid global expansion of biologics and peptide therapeutics, demand for advanced LAI drug delivery technologies is on the rise. InnoCore aims to meet this demand and thus realize its mission to improve patient health and treatment convenience.

At the helm of InnoCore’s next growth phase, Hans will oversee the strategic execution of:

- Expansion of global partnerships with biotech and pharma companies;
- Acceleration of InnoCore’s proprietary LAI technology platform;
- Driving innovation toward clinical and commercial success for customers; and

Strengthening operational and development capabilities.

## About InnoCore

InnoCore Pharmaceuticals is a Netherlands‑based drug development company specializing in long‑acting injectable (LAI) formulations using proprietary biodegradable polymer technologies. The company partners with global pharmaceutical and biotech companies to develop innovative, patient‑friendly LAI solutions for biologics, peptides, and small molecules.

[Hans CEO “I am excited to join InnoCore at this pivotal moment. The company's scientific excellence, platform strength, and commitment to improving patient outcomes are exceptional. I look forward to working with our customers and the team to shape InnoCore's next phase of growth and impact."” Meet Hans](https://innocorepharma.com/company/people/hans-de-backer/)
[Alexander Chairman “"Hans brings the leadership qualities and strategic clarity needed to accelerate InnoCore's ambition. His strong background in scaling life science organizations makes him uniquely positioned to guide InnoCore toward becoming the global partner of choice for LAI drug development."” Meet Alexander](https://innocorepharma.com/company/people/alexander-vos/)

Related insights

[26 July 2018 | Funding InnoCore and Merck enter global collaboration Merck and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery Technology. Read the full story](https://innocorepharma.com/news-events/innocore-and-merck-enter-global-collaboration/)
[11 September 2020 | Funding Bill & Melinda Gates Foundation Grant Awarded InnoCore Pharmaceuticals has been awarded a grant by the Bill & Melinda Gates Foundation to develop a long-acting injectable contraceptive implant. Read the full story](https://innocorepharma.com/news-events/innocore-awarded-grant-by-the-bill-melinda-gates-foundation-in-contraception/)
[01 January 2021 | Funding InnoCore leads Consortium in Influenza vaccines InnoCore Pharmaceuticals has secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch. Read the full story](https://innocorepharma.com/news-events/innocore-leads-consortium-in-influenza-vaccines/)